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ABSTRACT 
Long-term exposure to high glucocorticoid levels induces memory impairment and neurodegeneration in Alz-
heimer’s disease (AD) by increasing the expression of amyloid β and tau hyperphosphorylation (pTau). Previous 
studies showed beneficial effects of flavonoids in neurodegenerative models. 5,6,7,4'-tetramethoxyflavanone 
(TMF) is one of the active ingredients in Chromolaena odorata (L.), which R. M. King and H. Rob discovered in 
Thailand. This study focused on the effects of TMF on dexamethasone (DEX)-induced neurodegeneration, amy-
loidogenesis, pTau expression, neuron synaptic function, and cognitive impairment and the potential mechanisms 
involved. Mice were intraperitoneally administered DEX for 28 days before being treated with TMF for 30 days. 
The mice were randomly divided into six groups (twelve mice per group): control; TMF administration (40 
mg/kg); pioglitazone administration (20 mg/kg); DEX administration (60 mg/kg); DEX administration plus TMF; 
and DEX administration plus pioglitazone. Behavioral tests showed that TMF significantly attenuated the memory 
impairment triggered by DEX. Consistently, TMF reduced DEX-induced amyloid beta production by reducing the 
expression of beta-site APP cleaving enzyme 1 (BACE1) and presenilin 1 (PS1), whereas it increased the gene 
expression of a disintegrin and metalloprotease 10 (ADAM10). TMF treatment also decreased pTau expression, 
inhibited phosphonuclear factor-kappa B (pNF-kB) and inhibited glycogen synthase kinase 3 (GSK-3) activity by 
increasing GSK3 phosphorylation (pGSK3). In addition, TMF also improved synaptic function by increasing the 
expression of synaptophysin (Syn) and postsynaptic density protein 95 (PSD95) while decreasing acetylcholine 
esterase activity. Conclusively, TMF provided neuroprotection against DEX-induced neurodegeneration. These 
findings suggest that TMF might have potential as a therapeutic drug for AD. 
 
Keywords: 5,6,7,4'-tetramethoxyflavanon, Alzheimer’s disease, amyloidogenesis, dexamethasone, neurodegen-
eration 
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INTRODUCTION 
Alzheimer’s disease (AD) is a neuro-
degenerative disorder leading to memory loss 
(Burns and Iliffe, 2009). AD pathology is re-
lated to an increase in amyloid beta (Aβ), 
which forms senile plaques, and hyperphos-
phorylated neuronal cytoskeleton protein (tau 
protein), which aggregates into a neurofibril-
lary tangle (NFT). Aβ is generated from the 
amyloid precursor protein (APP) by beta-site 
APP cleaving enzyme 1 (BACE1) and gamma 
secretase (O'Brien and Wong, 2011). In addi-
tion, Aβ impairs neuronal synaptic function 
by decreasing the expression of both presyn-
aptic molecules, such as synaptophysin (Syn), 
and postsynaptic proteins, such as postsynap-
tic density protein 95 (PSD95), to decrease 
neuronal function, decrease learning and 
memory behavior and induce loss of short-
term memory (Liu et al., 2010). Previous 
studies have demonstrated the involvement of 
the amyloidogenic pathway and high levels of 
glucocorticoids (GCs). Long-term exposure 
to high GC levels causes an AD-like pathol-
ogy associated with an increase in Aβ produc-
tion and hyperphosphorylated tau (pTau), 
which are the major causes of AD. Chronic 
stress increases GC secretion from the adrenal 
gland and binds with cytoplasmic glucocorti-
coid receptor (GR), resulting in GR activa-
tion; then, the active GR forms a homo-oligo-
mer structure and translocates into the nu-
cleus. In the nucleus, the GR oligomer acti-
vates APP and BACE-1 transcription by di-
rectly binding with the glucocorticoid re-
sponse element (GRE) and regulates tran-
scription to increase APP and β-secretase ex-
pression (Wang et al., 2011). Moreover, the 
administration of dexamethasone (DEX) to a 
transgenic mouse model of AD increased 
NFT pathology (Joshi et al., 2013). Tau pro-
tein stabilizes the axon microtubules of neu-
rons and increases microtubule flexibility, 
leading to a healthy, functional neuron. Tau 
protein shows high expression in neurons but 
very low expression in astrocytes and oli-
godendrocytes (Billingsley and Kincaid, 
1997). Tau protein is phosphorylated by gly-
cogen synthase kinase (GSK3) (Billingsley 
and Kincaid, 1997; Taniguchi et al., 2001) 
and is a key component of NFT. Therefore, 
activation of a disintegrin and metalloprote-
ase 10 (ADAM10), inhibition of BACE1 and 
presenilin 1 (PS1) and reduction of NFT are 
potential treatments for AD. Pioglitazone is a 
peroxisome proliferator-activated receptor 
gamma (PPARγ) agonist. Many previous 
studies have demonstrated that pioglitazone 
has a pharmacological advantage in several 
AD models (Maeshiba et al., 1997; Yan et al., 
2003). Pioglitazone has been shown to reduce 
Aβ plaques in APPV717I transgenic mice 
(Heneka et al., 2005). In addition, pioglita-
zone also reduced the expression of BACE1 
and Aβ1-42 and improved memory impair-
ment in APP transgenic mice (Pedersen et al., 
2006; Sastre et al., 2003; Sastre et al., 2006). 
Thus, pioglitazone was used as a positive con-
trol in this study. 
5,6,7,4'-tetramethoxyflavanone (TMF, 
Figure 1) is a flavonoid isolated from Chro-
molaena odorata (L.) by R.M. King & H. 
Rob. Flavonoids have a wide range of benefi-
cial effects, including anti-oxidative and anti-
inflammatory effects, and improves memory 
deficits in mice (Gonzalez-Gallego et al., 
2010; Panahi et al., 2016; Kao et al., 2010; 
Mori et al., 2012). This study aimed to inves-
tigate the neuroprotective activity of TMF and 
explore the underlying mechanisms of action. 
 
Figure 1: The chemical structure of 5,6,7,4'-tetra-
methoxyflavanone (TMF) 
 
 
MATERIALS AND METHODS 
Chemicals and reagents 
Dexamethasone sodium phosphate Lo-
dexa-5® was purchased from L.B.S. Labora-
tory Ltd. (Bangkok, Thailand). Mouse anti-β-
EXCLI Journal 2020;19:16-32 – ISSN 1611-2156 
Received: October 31, 2019, accepted: December 04, 2019, published: January 02, 2020 
 
 
18 
actin-HRP conjugate monoclonal antibody, 
rabbit antisera against phosphonuclear factor-
kappa B (p-NF-κB) and rabbit polyclonal an-
tisera against phospho-Tau (Ser202) were 
purchased from Cell Signaling Technology, 
Inc. (Danvers, MA, USA). Mouse monoclo-
nal antibody against synaptophysin, mouse 
monoclonal antibody against PSD95, mouse 
monoclonal antibody against GSK3, mouse 
monoclonal antibody against phospho-GSK3 
(Tyr279/Tyr216), rabbit antisera against ac-
tive caspase 3 (cleaved form), goat polyclonal 
antisera against mouse IgG-peroxidase conju-
gate and mouse monoclonal antisera against 
rabbit IgG-peroxidase conjugate were pur-
chased from EMD Millipore Corporation 
(Temecula, CA, USA). 
 
Isolation of TMF 
Air-dried leaves of C. odorata (8.0 kg) 
were pulverized and extracted successively 
with n-hexane, EtOAc and MeOH at room 
temperature. The filtered solutions were evap-
orated to dryness under reduced pressure at 
40–45 °C to obtain the hexane (663.24 g), 
EtOAc (956.7 g) and MeOH (546.25 g) ex-
tracts, respectively. The hexane extract (600.0 
g), which has high neuroprotective activity in 
SK-N-SH cells, was fractionated by silica col-
umn chromatography. The first fraction con-
tained fatty acids and nonpolar components. 
The second fraction (129.3 g) was chromato-
graphed on a Sephadex LH-20 column, which 
was eluted with 40 % CH2Cl2 in MeOH to 
furnish 3 fractions, and the second fraction 
was crystallized from MeOH to give 5,6,7,4'-
tetramethoxyflavanone (5.78 g) as the major 
constituent. The structure of this compound 
was confirmed by comparison of the spectro-
scopic data with the literature values 
(Suksamrarn et al., 2004). 
 
Animals 
Male ICR mice weighing 35-40 g (6-8 
weeks old) were obtained from the National 
Laboratory Animal Center, Mahidol Univer-
sity, Salaya, Nakorn Pathom, Thailand. The 
mice were housed under a 12:12 h dark/light 
cycle at a constant temperature (25±1 °C) and 
ad libitum normal chow food and water. All 
experimental procedures were approved by 
the Institutional Animal Care and Use Com-
mittee at the Faculty of Medicine, Chiang Mai 
University, (Permit number: 30/2559) and 
performed in accordance with the National In-
stitute of Health Guide for the Care and Use 
of Laboratory Animals. 
 
Animal treatment 
The mice were randomly assigned to the 
following six groups (twelve mice per group): 
(1) control; (2) TMF administration (40 
mg/kg); (3) pioglitazone administration (20 
mg/kg); (4) DEX-administration (60 mg/kg); 
(5) DEX administration plus TMF; (6) DEX 
administration plus pioglitazone. 
The mice in the DEX-administration 
group, the DEX-administration plus TMF 
group, and the DEX-administration plus 
pioglitazone group received daily intraperito-
neal injections for 58 days. The mice in the 
DEX-administration plus TMF group, the 
pioglitazone group, the TMF (40 mg/kg) 
group and the pioglitazone (20 mg/kg) group 
received oral administration daily for 30 days 
starting from day 28 of the DEX injection. All 
control animals were given normal saline with 
the same volume via intraperitoneal injection 
and oral administration, respectively. After 
treatment, the mice were submitted to behav-
ioral tests and then sacrificed by decapitation. 
The brain tissues were removed for further 
studies. RNA for qRT-PCR was extracted 
from the hippocampal region, and protein ex-
traction was performed with the whole brain 
of mice in each group for the protein studies.  
 
Open-field test 
The open-field test is a method for meas-
uring locomotion and anxiety (Seibenhener 
and Wooten, 2015). The open-field apparatus 
size was 72 x 72 cm with a 36-cm wall. The 
mice were placed into the open-field appa-
ratus at one corner and allowed to explore the 
apparatus for 5 min. After 5 min, the mice 
were returned to their home cages, and the 
open-field box was cleaned. The mice were 
exposed to the apparatus for two consecutive 
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days. Every experiment was recorded by 
video camera and analyzed using the SMART 
system (Panlab Harward Apparatus; Biosci-
ence Company, MA, USA). 
 
Morris water maze (MWM) test 
Spatial memory was assessed using the 
Morris water maze (MWM) test (Vorhees and 
Williams, 2006), which consisted of a five-
day location navigation training and a probe 
test on day six. The maze was a circular pool 
(100 cm in radius and 40 cm high) that was 
filled with water at a temperature of approxi-
mately 23±1 °C. The tank was divided into 
four quadrants, one of which contained a cir-
cular platform (10 cm diameter) placed at a 
fixed position two cm below the surface of the 
water. Oriented navigation trials were per-
formed four times per day for five consecu-
tive days with a constant interval of one hour. 
For all training trials, the time that it took the 
mouse to reach the submerged platform (es-
cape latency) was recorded to assess spatial 
learning ability. On the sixth day, another set 
of tests consisting of a trial with the hidden 
platform was conducted. The time required 
for individual mice to find the platform was 
two minutes. The time required to swim to the 
target quadrant and the swimming distance 
were recorded using SMART video tracking 
software (Panlab Harward Apparatus; Biosci-
ence Company, Holliston, MA, USA). 
 
Measurement of secretase enzyme by real-
time quantitative polymerase chain reaction 
(qRT-PCR)  
Total RNA was isolated from the hippo-
campal region for each group using TRIzol 
reagent (MACHEREY-NAGEL GmbH and 
Co. KG, Düren, Germany). For all RNA sam-
ples, the purity and quantity were determined 
with a Nanodrop. One microgram of total 
RNA was used for cDNA synthesis with a Re-
verTraAceqPCR RT kit (Toyobo, Tokyo, Ja-
pan). PCR amplification was performed using 
a KOD SYBR qPCR kit (Toyobo, Tokyo, Ja-
pan) with an ABI PRISM 7500 Sequence De-
tection system (Applied Biosystems, Foster 
City, CA, USA). Primer sets specific for PS1, 
BACE1, ADAM10, APP and GAPDH were 
designed. The primers sequences are shown 
below.  
 
PS1: 
Forward: 5’GACGGTCAGCTAATCTACAC3’ 
Reverse: 5’GATAAATACCAGGGCCATGAG3’ 
BACE1: 
Forward: 5’TGTGCCCTACACCCAG3’ 
Reverse: 5’GTATAGCGAGTGGTCGAT3’ 
ADAM10: 
Forward: 5’GCCAGCCTATCTGTGGAAACGGG3’ 
Reverse: 5’TTAGCGTCGCATGTGTCCCATTTG3’ 
APP: 
Forward: 5’GCTGCCCAGCTTGGCACTGC3’ 
Reverse: 5’GGCAACGGTAAGGAATCACGATGT-
GGGTG3’ 
GAPDH: 
Forward: 5’AGAAGGTGGTGAAGCAGGCATC3’ 
Reverse: 5’CGAAGGTGGAAGAGTGGGAGTTG3’ 
 
Histological analysis by hematoxylin and 
eosin (H&E) staining 
The coronal sections were prepared and 
stained with hematoxylin and eosin (H&E) to 
observe the morphological changes. After 
treatment, the mouse brain tissues were im-
mediately removed and fixed in 10 % forma-
lin in phosphate-buffered saline (PBS), pH 
7.4, and embedded in paraffin. Then, the cor-
onal brain tissues were sectioned at 20-μm 
thickness using a microtome (Leica, Ger-
many) and stained with H&E for observation 
pathological changes under a light micro-
scope (Olympus AX70, Tokyo, Japan). 
 
Terminal deoxynucleotidyl transferase UTP 
nick end labeling (TUNEL) assay 
TUNEL staining was used to detect cell 
apoptosis based on DNA fragmentation 
caused by apoptotic signaling cascades. The 
brain tissues were fixed in 4 % formaldehyde, 
embedded in paraffin, and sectioned at a 
thickness of 4 µm. The sections were depar-
affinized and rehydrated. Then, TUNEL 
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staining was performed according to the man-
ufacturer’s instructions with a TUNEL assay 
kit (Roche Diagnostics GmbH, Mannheim, 
Germany). Finally, the total number of cells 
and TUNEL-positive cells were observed un-
der light microscopy. Five high-power fields 
(×400) were randomly selected, and the num-
ber of apoptotic cells was counted in each 
field. The apoptosis index (AI) = number of 
positive cells per number of total cells. 
 
Acetylcholinesterase (AChE) level 
Brain tissues were collected and placed in 
lysis buffer. Brain homogenates were incu-
bated with 100 µl of Ellman’s reagent and 190 
µl of 75 mM propionyl thiocholine iodide at 
37°C for 20 min. Absorbance values were 
read at 405 nm in a microplate reader every 5 
sec for 2 min. 
 
Western blotting 
After treatment, brain tissues were col-
lected and homogenized with lysis buffer (1.5 
mM MgCl2, 10 mM KCl, 20 mM HEPES, 1 
mM EDTA, 1 mM EGTA, 250 mM sucrose, 
0.1 mM phenylmethylsulfonyl fluoride, 1 
mM dithiothreitol, and proteinase inhibitor; 
pH 7.9). The homogenate was centrifuged at 
10,000 rpm for 15 min at 4 °C, and the super-
natant was collected. The protein concentra-
tion was measured using a Bradford assay 
with bovine serum albumin (BSA) as the 
standard. Equal amounts of protein sample 
were loaded in each well of a 10-15 % sodium 
dodecylsulfate-polyacrylamide gel for SDS-
PAGE. The proteins were transferred to a pol-
yvinylidine fluoride (PVDF) membrane (Im-
mobilon-P, Millipore, Bedford, MA, USA), 
which was incubated with 5 % nonfat milk at 
4 °C overnight. 
The membrane was then incubated with 
the following primary antibodies: rabbit anti-
pTau (1:1,000, Cell Signaling); mouse anti-
GSK3 (1:1,000, Millipore); mouse anti-
pGSK3 (1:1,000, Millipore); mouse anti-
PSD95 (1:1,000, Millipore); mouse anti-syn-
aptophysin (1:1,000, Millipore); rabbit anti-
cleaved caspase 3 (1:1,000, Millipore); and 
anti-phospho NF-kB and mouse anti-beta-ac-
tin (1:1,000, Cell Signaling) at 4 °C over-
night. The membrane was washed three times 
with TBST and then incubated with horserad-
ish peroxidase-conjugated secondary anti-
body for 2 h at room temperature. The chem-
iluminescent bands were visualized using 
ECL substrate solution (Millipore, MA, USA) 
before being exposed to X-ray films. The den-
sitometric analysis was performed using a 
scanning densitometer and analyzed using 
ImageJ software (National Institute of Health, 
Bethesda, MD, USA). 
 
Statistical analysis 
Animal behavioral data were analyzed us-
ing two-way analysis of variance (ANOVA) 
with repeated measures followed by a post 
hoc test. All other values are presented as the 
mean ± SEM. The significance of the differ-
ence between the means of the two groups 
was analyzed by one-way analysis of variance 
(ANOVA) and Tukey’s post‐hoc multiple test 
for comparisons among the experimental 
groups. A value of p < 0.05 was considered 
significant. 
 
RESULTS 
Effects of TMF on anxiety behavior after 
chronic DEX exposure 
The anxiety behavior in mice chronically 
exposed to DEX and treated with TMF at a 
dosage of 40 mg/kg for 30 days was evaluated 
using the open-field test (Figure 2A). DEX 
treatment significantly decreased the time 
spent in the central area compared with that in 
the control group (p< 0.01), but there was no 
significant difference in the TMF and 
pioglitazone treatment groups compared with 
the control group. TMF treatment in DEX 
mice resulted in a significantly increased time 
in the central area compared with that of DEX 
group at a level similar to that of the pioglita-
zone group (p< 0.05) (Figure 2B). The time 
spent in the periphery was analyzed and is 
shown in Figure 2C. The DEX group showed 
significantly increased time in the periphery 
compared with the control group (p<0.05). 
No differences were evident in the TMF and 
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pioglitazone groups compared with the con-
trol group. The DEX plus TMF or DEX plus 
pioglitazone groups showed a significant de-
crease in the time spent in the periphery com-
pared with the DEX group (p<0.05). Anxiety 
behavioral outcomes were investigated by ob-
serving the frequency of rearing and groom-
ing, as shown in Figure 2D and Figure 2E. 
The frequency of both behaviors was signifi-
cantly decreased in the DEX group compared 
with that in the control group (p<0.01 and 
p<0.001, respectively), but no differences 
were observed in the TMF and pioglitazone 
groups compared with the control group. Sig-
nificantly increased rearing and grooming 
were found in the DEX plus TMF group 
(p<0.01 and p<0.05). The DEX plus pioglita-
zone group was also found to exhibit signifi-
cant increases in both behaviors (p<0.01). 
  
 
 
 
Figure 2: The effect of TMF on anxiety behavioral outcomes was investigated by open-field test (OFT). 
(A) The tracking for the OFT by the SMART program. (B) The time spent in central area of the open-
field box. (C) The time spent in periphery of the open-field box. (D) The frequency of rearing behavior 
in 5 min. (E) The frequency of grooming behavior in 5 min. The data are the mean ± SEM from three 
independent experiments (**p<0.01, ***p<0.001 compared with the control group, #p<0.05, ##p<0.01 
compared with the DEX group).
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TMF treatment suppresses the cognitive  
impairment induced by DEX in mice  
The spatial learning and memory ability 
of the mice were evaluated by the Morris Wa-
ter Maze Test. The tracking for MWM on the 
last training day is shown in Figure 3A, and 
the tracking for the trial test is shown in Fig-
ure 3B. Figure 3C-D show that the mice in the 
DEX-administration group had a significant 
impairment in spatial learning ability during 
the 5-day test, as demonstrated by the longer 
time needed to find the platform compared 
with the control group. A significant differ-
ence in escape latency time was observed in 
the DEX plus TMF treatment group and the 
DEX plus pioglitazone group on the last train-
ing day compared with that in the DEX group 
(p<0.01, p<0.001, respectively). Pioglitazone 
treatment with DEX administration also re-
sulted in a significant decrease in the time 
needed to find the platform compared with 
TMF treatment with DEX administration 
(p<0.05). The hidden platform was removed 
to perform a probe trial. As shown in Figure 
3E, the DEX-administration group showed a 
significant decrease in the time spent in the 
target quadrant (p<0.001). However, the mice 
in the DEX administration plus TMF group or 
the pioglitazone group displayed remarkable 
increases in the time spent in the target quad-
rant compared with those in the DEX group 
(p<0.01, p<0.01, respectively). In addition, in 
normal mice, the administration of TMF or 
pioglitazone did not show any effects com-
pared with the control group. The swimming 
speed in each group is shown in Figure 3F; the 
results showed no significant differences be-
tween the groups. The results indicate that 
DEX-induced mice have an impairment in 
spatial learning and memory, while TMF or 
pioglitazone treatment could restore cognitive 
function. 
Effects of TMF on amyloidogenesis in 
mouse brain 
Amyloidogenesis involves gene expres-
sion related to amyloid beta (Aβ) production, 
leading to memory impairment pathology. 
The effects of TMF on amyloidogenic-related 
gene expression were investigated for the 
genes ADAM10, BACE1, PS1 and APP by 
real time-polymerase chain reaction (RT-
PCR) (Figure 4). The expression of the 
ADAM10 gene was significantly decreased in 
the DEX group compared with that in the con-
trol group (p<0.01). There was no significant 
difference between the TMF or pioglitazone 
groups and the control group. The mice in the 
DEX administration plus TMF group or the 
pioglitazone group displayed remarkably in-
creased ADAM10 gene expression compared 
with the DEX group (p<0.01 and p<0.001). 
Interestingly, the DEX administration plus 
pioglitazone group showed a significant in-
crease in the ADAM10 gene compared with 
the DEX administration plus TMF group 
(p<0.001). The DEX group showed a signifi-
cant increase in BACE1 and PS1 gene expres-
sion (p<0.01) compared with the control 
group. The mice in the DEX administration 
plus TMF group had significantly decreased 
BACE1 gene expression (p<0.05) but did not 
show a significant difference in PS1 gene ex-
pression compared with the DEX group. In-
terestingly, the mice in the DEX administra-
tion plus pioglitazone group had significantly 
decreased BACE1 and PS1 gene expression 
(p<0.001 and p<0.01) compared with the 
DEX group (Figure 4B, C). However, APP 
gene expression was not found to be signifi-
cantly different between the groups (Figure 
4D). 
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Figure 3: The effect of TMF on learning and memory behavior performance was investigated by Morris 
water maze test. (A) The tracking for the last training day by the SMART program. (B) The tracking for 
the trial test. (C) Escape latency time for 5 days. (D) Escape latency time on the last day. (E) Time spent 
in target quadrant during the probe trial. (F) Swimming speed. The data are the mean ± SEM from three 
independent experiments (***p<0.001 compared with the control group, ##p<0.01, ###p<0.001 compared 
with the DEX group, $p<0.05 compared with pioglitazone treatment in the DEX administration group). 
 
 
TMF attenuates Tau hyperphosphorylation 
(pTau) expression in DEX-induced mice 
pTau levels were investigated by Western 
blotting (Figure 5A-B). pTau levels were sig-
nificantly increased in the DEX group com-
pared with the control group (p<0.001) and 
did not show significant differences in the 
TMF or pioglitazone treated normal mice 
compared with the control group. Treatment 
with TMF and pioglitazone in the DEX ad-
ministration group had significantly de-
creased pTau levels compared with the DEX
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Figure 4: RT-PCR performance to investigate the effect of TMF on amyloidogenic-related gene expres-
sion. The data were analyzed as the fold change of mRNA expression of ADAM10 expression (A), 
BACE1 (B), PS1 (C) and APP (D). The data are the mean ± SEM from three independent experiments 
(*p<0.05, **p<0.01 compared with the control group, #p<0.05, ##p<0.01, ###p<0.001 compared with the 
DEX group, $$p<0.01 compared with pioglitazone treatment in the DEX administration group). 
 
 
group (p<0.05 and p<0.001). However, there 
was a significant decrease in pTau in the 
pioglitazone treatment in DEX administration 
group compared with the TMF treatment in 
DEX administration group (p<0.01).  
We next further investigated the effect of 
TMF on GSK3, pGSK3 and nuclear factor-
kappa B phosphorylation (pNF-kB) expres-
sion by Western blot, as shown in Figure 5C, 
D and E, respectively. The DEX group signif-
icantly increased GSK3 expression (p<0.05) 
and decreased the pGSK3 level (p<0.01) 
compared with the control group. The TMF or 
pioglitazone treated normal mice did not 
show a significant difference in GSK3 expres-
sion or pGSK3 levels compared with the con-
trol group. The DEX administration mice plus 
TMF had a significantly increased pGSK3 
level (p<0.05); however, there was no signif-
icant difference in GSK3 expression com-
pared with the DEX group. Moreover, GSK3 
expression was significantly decreased in 
mice administered DEX plus pioglitazone 
compared with the DEX group (p<0.05). 
pGSK3 levels were significantly increased in 
the DEX administration mice plus pioglita-
zone (p<0.01) compared with the DEX group. 
Moreover, pNF-kB was also significantly re-
duced in the DEX administration plus TMF or 
pioglitazone groups (p<0.05 and p<0.01, re-
spectively). 
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Figure 5: The attenuation effect of TMF on pTau expression. (A) Representative of GSK3, pGSK3, 
pNF-κB and pTau protein expression as determined by Western blotting. Brain tissues were used for 
electrophoresis and immune blotting. The bands were analyzed and are presented as a histogram, with 
actin as the control. (B) The quantitative results of all groups for pTau expression. (C) The quantitative 
results of all groups for GSK3 expression. (D) The quantitative results of all groups for pGSK3 expres-
sion. (E) The quantitative results of all groups for pNF-κB expression. The data are the mean ± SEM 
from three independent experiments (*p<0.01, **p<0.01, ***p<0.001 compared with the control group, 
#p<0.05, ##p<0.01, ###p<0.001 compared with the DEX group, $$p<0.01 compared with pioglitazone treat-
ment in the DEX administration group).
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Effect of TMF on neuronal morphology 
change and neuronal apoptosis 
Neuronal morphology changes were eval-
uated by H&E staining (Figure 6A). The hip-
pocampus area from the DEX group showed 
markedly increased pyknotic nuclei com-
pared with the control group (black arrow). 
Conversely, a reduction of neuronal positive 
pyknotic nuclei was observed in the mice in 
the DEX plus TMF group or the pioglitazone 
group compared with the DEX group. Next, 
we investigated neuronal cell apoptosis utiliz-
ing a TUNEL assay to stain apoptotic neurons 
dark brown (Figure 6B, C). The neuronal cells 
in the hippocampus showed an increase in 
TUNEL-positive cells (black arrow) in the 
DEX group compared with the control 
(p<0.001). A decrease in TUNEL-positive 
cells was found in mice administered DEX 
plus TMF or pioglitazone. To determine neu-
ronal cell apoptosis, the TUNEL-positive 
cells were counted and analyzed as percent-
ages of the control as shown in Figure 6C. The 
DEX group showed a significant increase in 
TUNEL-positive cells compared with the 
control group (p<0.001) but there was no sig-
nificant difference in the TMF and pioglita-
zone group compared with the control group. 
A significant decrease in TUNEL-positive 
cells was found in the DEX plus pioglitazone 
group (p<0.05) compared with the DEX 
group. DEX plus TMF induced a decrease in 
TUNEL-positive cells compared with the 
DEX group; however, the difference was not 
significant. 
 
 
 
 
Figure 6: TMF attenuates neuronal apoptosis. Brain tissues were stained with H&E to determine neu-
ronal morphology in the hippocampus region (A). TUNEL assay was used to investigate cell apoptosis 
in brain tissues (B), TUNEL-positive cells were analyzed as % of control to compare all groups (C). 
Representative cleaved caspase 3 levels as determined by Western blotting are presented in a histo-
gram (with actin as the control) (D). The data are the mean ± SEM from three independent experiments 
(***p<0.001 compared with the control group, #p<0.05 compared with the DEX group).
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The expression of cleaved caspase3, 
which is known to be a crucial mediator of 
apoptosis, was determined by Western blot-
ting (Figure 6D). DEX led to an increase in 
cleaved caspase 3 levels compared with the 
control group (p<0.001). TMF or pioglitazone 
treatment in normal mice did not induce sig-
nificant differences in cleaved caspase 3 lev-
els compared with the control group. TMF 
treatment in mice administered DEX reduced 
cleaved caspase 3 levels but showed no sig-
nificant differences compared with the DEX 
group. A significant reduction of cleaved 
caspase 3 levels was found in mice adminis-
tered with DEX plus pioglitazone compared 
with DEX (p<0.05). 
 
TMF improved neuronal synaptic function 
in DEX-induced mice  
AChE activity was investigated in the 
brain in all groups (Figure 7A). AChE activity 
in the TMF or pioglitazone group was not sig-
nificantly different; however, AChE activity 
was significantly increased in the DEX group 
compared with the control group (p<0.001). 
Treatment with TMF in DEX–induced mice 
induced a significant decrease AChE activity 
(p<0.05) compared with the DEX group. In 
addition, treatment with pioglitazone in DEX-
induced mice induced a significant decrease 
in AChE activity (p<0.01). Expression of the 
presynaptic protein synaptophysin and the 
postsynaptic density protein PSD95 was de-
termined by Western blot (Figure 7B-C). The 
results showed that both proteins were 
 
 
Figure 7: Improvement effect of TMF on neuronal synaptic function in memory-impaired mice. (A) Ac-
etylcholinesterase activity assay in all groups. (B) and (C) Synaptophysin and PSD95 protein expression 
as determined by Western blotting; the results are presented as a quantitative histogram. The data are 
the mean ± SEM from three independent experiments (*p<0.01, ***p<0.001 compared with the control 
group, #p<0.05, ##p<0.01, ### p<0.001 compared with the DEX group). 
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decreased in the DEX group compared with 
the control group. Interestingly, pioglitazone 
treatment in normal mice also induced a sig-
nificant increase in synaptophysin expression 
(p<0.01) compared with the control. TMF 
treatment in DEX-induced mice significantly 
increased the levels of the post-synaptic pro-
tein PSD95 (p<0.05), while the levels of the 
presynaptic protein synaptophysin tended to 
increase, but not significantly, compared with 
the DEX group. Pioglitazone treatment in 
DEX-induced mice also significantly in-
creased the levels of both the presynaptic pro-
tein synaptophysin (p<0.05) and the postsyn-
aptic protein PSD95 (p<0.05) compared with 
those in the DEX group. 
 
DISCUSSION 
Long-term exposure to high GC levels 
causes AD-like pathology by increasing neu-
rodegeneration, which is a term that describes 
the progressive loss of the structure or func-
tion of neurons (Bossy-Wetzel et al., 2004). 
The evidence for the relationship between 
chronic GC exposure and AD showed that the 
increase in Aβ and pTau expression caused 
memory deficits (Green et al., 2006). Moreo-
ver, chronic GC exposure leads to neuro-
degeneration in the brain cortex and hippo-
campus (Hu et al., 2016). DEX is a steroid 
drug widely used in inflammatory diseases. 
The structure of DEX is similar to that of GC; 
their action is through binding GR, and they 
also show effects similar to those of GC, in-
cluding neurodegeneration. Several studies 
have demonstrated that DEX induces an AD 
model in rodents by increasing pTau, Aβ ex-
pression, and memory impairment (Li et al., 
2012; Tongjaroenbuangam et al., 2013., 
Lesuis et al., 2018; Ouanes and Popp, 2019). 
This study aimed to study the neuroprotective 
effects of TMF and its possible mechanisms 
in DEX–induced mice. TMF alleviated DEX-
stimulated amyloidogenesis and neuronal cell 
death as well as maintaining the balance of the 
cholinergic system, and such effects might be 
related to cognitive function enhancement. 
The behavioral study demonstrated that 
learning and memory impairment was ob-
served in mice exposed to DEX, whereas 
TMF treatment attenuated the deterioration of 
spatial learning and memory triggered by 
DEX. GC induces neurodegeneration associ-
ated with an increase in Aβ production, which 
is a major cause of AD (Murphy and LeVine, 
2010). The aggregates of Aβ peptide are a 
pathological hallmark of AD. The production 
of the Aβ peptide is through the activity of the 
BACE1 and PS1, which are widely consid-
ered to have a crucial role in initiating AD pa-
thology (O'Brien and Wong, 2011). Overex-
pression of BACE1 in the brain regions was 
observed in AD patients. Several lines of evi-
dence have demonstrated that a reduction of 
BACE1 resulted in decreased Aβ production 
in several mouse models of AD (Kim et al., 
2018; Cai et al., 2012; Xue et al, 2015). Aβ 
acts as a major trigger of neuronal and glial 
pro-inflammatory activation. Following acti-
vation, both neuronal cells and glial cells pro-
duced inflammatory mediators, such as tumor 
necrosis factor-α (TNF-α), interleukin 1, beta 
(IL-1β), nitric oxide (NO) and cyclooxygen-
ases (COXs), which was mediated by NF-κB 
(Ferrera et al., 2014; Carrero et al., 2012). In-
creased NF-κB activity plays a central role in 
regulating the expression of inflammatory 
genes. Upon activation, the IκBα protein, 
which is the inhibitory subunit of the NF-κB, 
undergoes phosphorylation and degradation, 
which enables the translocation of the NF-κB 
p65 subunit from the cytosol into the nucleus. 
Several lines of evidence have demonstrated 
that inflammation has an important role in the 
amyloidogenesis pathway via activating NF-
κB signaling. Inflammation has been reported 
to result in increased APP processing and the 
accumulation of Aβ peptides (Ringheim et al., 
1998; Yamamoto et al., 2007). NF-κB acti-
vates the BACE1 promoter and upregulates 
the expression of BACE1 (Chen et al., 2012). 
In addition, NF-κB also regulates the tran-
scriptional activity of APP and gamma-secre-
tase promoters (Chami et al., 2012). Previous 
studies have reported that chronic GC expo-
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sure induced neuroinflammation by activat-
ing NLR family pyrin domain containing 1 
(NLRP1) inflammasome in brain tissues and 
inducing neuronal cell death (Zhang et al., 
2017). Several studies have reported that GC 
activates transcription to increase APP and β-
secretase expression (Sotiropoulos et al., 
2008; Green et al., 2006). Previous studies 
have demonstrated that the anti-inflammatory 
activity of flavonoids from plants occurs 
through suppressing NF-κB signaling (Naik 
et al., 2017; Ruiz et al., 2007). Therefore, sup-
pressing NF-κB signaling in AD could pre-
vent the amyloidogenesis pathway and neuro-
degeneration. We present evidence that DEX 
markedly upregulated BACE1 and PS1 and 
downregulated ADAM10 mRNA levels and 
reduced the accumulation of Aβ in brain tis-
sues. TMF significantly increased the expres-
sion of α-secretase and decreased the produc-
tion of the β-secretase without altering APP 
levels. Our results demonstrated that TMF de-
creased pNF-κB and the production of NO. 
Therefore, there is a possibility that the TMF 
stimulated the non-amyloidogenic processing 
of APP, and enhanced α-secretase levels also 
might decrease BACE1 expression through 
the negative regulation of NF-κB.  
GSK3 is an important kinase enzyme 
leading to the regulation of Aβ accumulation 
and pTau (Terwel et al., 2008; DaRocha-
Souto et al., 2012). Abnormal tau protein in-
duces the loss of their functions, disassociat-
ing from microtubules, leading to destabiliza-
tion of the microtubules, the disruption of 
nerve impulses and loss of memory formation 
(Chatterjee et al., 2009; Lambourne et al., 
2005). Moreover, pTau bound together gener-
ates NFT and aggregated in neurons, activat-
ing the apoptosis pathway and resulting in 
neuronal cell death (Lee et al., 2005). Inhibi-
tion of GSK3 reduced tau phosphorylation. 
DEX upregulated pTau expression by activat-
ing GSK3 and down regulating pGSK3 ex-
pression. TMF tends to decrease GSK3 ex-
pression but significantly increased pGSK3 
expression and significantly decreased pTau. 
Our results also demonstrated that TMF atten-
uated pTau and pGSK3 levels in mice treated 
with DEX, which indicated that TMF reduced 
tau phosphorylation, which may be associated 
with the GSK-3 signaling pathway. 
Recent studies have demonstrated that an 
imbalance of the cholinergic system in the 
central nervous system (CNS), which is re-
lated to learning and memory impairment, oc-
curred during amyloidogenesis (Garcia-Al-
loza et al., 2005; Liu et al., 2010). Neuron 
synaptic function was reduced in AD patients, 
which was related to a decrease in neurotrans-
mitters, such as ACh, by increasing AChE ac-
tivities (Garcia-Ayllon et al., 2010). Moreo-
ver, AD patients also show changes in synap-
tic molecular expression that are important to 
neuronal synaptic function, especially, pre-
synaptic molecules, such as synaptophysin, 
and postsynaptic proteins, such as PSD95 
(Shao et al., 2011; Tampellini et al., 2010). 
This study found that DEX caused a decrease 
in ACh levels via elevating AChE activity. 
However, TMF treatment markedly normal-
ized the cholinergic system in the mouse 
brain. We next determined the expression of 
both synaptic molecules. DEX decreased both 
synaptophysin and PSD95 expression levels, 
while TMF treatment upregulated the expres-
sion of PSD95. However, TMF tended to in-
crease synaptophysin expression with no sig-
nificant difference compared with DEX treat-
ment alone.  
Many studies have suggested that apopto-
sis plays an important role in AD. Apoptosis 
leads to progressive neuronal cell loss in AD 
pathogenesis (Obulesu et al., 2014). DEX 
treatment induced neuronal cell damage in 
several brain areas, including the cortex and 
hippocampus. Interestingly, TMF rescued the 
loss and damage of neurons triggered by DEX 
and enhanced cognitive ability in mice. Brain 
histology demonstrated that the neuronal cell 
morphology was changed in DEX mice, and 
TMF treatment induced improvement. Our re-
sults also showed markedly increased 
TUNEL-positive cells in DEX mice and a 
small number of TUNEL-positive cells in the 
brains of the TMF-treated group. Further-
more, TMF also decreased the levels of 
cleaved caspase-3 protein in DEX-mice. 
EXCLI Journal 2020;19:16-32 – ISSN 1611-2156 
Received: October 31, 2019, accepted: December 04, 2019, published: January 02, 2020 
 
 
30 
These results are related to the decrease in the 
number of apoptotic cells, clearly indicating 
the anti-apoptotic effects of TMF in DEX 
mice. 
 
CONCLUSIONS 
In conclusion, it is evident that TMF treat-
ment improves learning and memory impair-
ment in DEX-induced mice by decreasing Aβ 
production and reducing pTau expression, re-
sulting in increased neuronal cell survival. 
Moreover, TMF improved neuronal cell syn-
aptic function by reducing AChE activity and 
increasing the expression of pre- and postsyn-
aptic molecules. In addition, our study is the 
first to report the effect of TMF in DEX-in-
duced mice. TMF might play a role in im-
proving learning and behavior and may offer 
neuroprotection against AD. 
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